Johnson & Johnson is an American multinational healthcare company specializing in pharmaceuticals and medical technologies. The company is focusing on medicine and MedTech to innovate and deliver breakthroughs in healthcare solutions. During the first quarter of 2025, JNJ made significant progress in its research and product development.
It advanced its pipeline with new developments like TREMFYA for inflammatory bowel disease, RYBREVANT plus LAZCLUZE for non-small-cell lung cancer, and OTTAVA, a soft tissue surgical robotic system.
JnJ’s strategic U.S. expansion
Additionally, Johnson & Johnson enhanced its neuroscience portfolio through the acquisition of Intra-Cellular Therapies.
In March 2025, JNJ announced plans to invest more than $55 billion in the US over the next four years. This investment aims to build three new advanced manufacturing facilities and expand several existing sites in the company’s Innovative Medicine and MedTech businesses. Increased investments in technology will help Johnson & Johnson accelerate drug discovery and development, support workforce training, and improve business operations.
While JNJ is a robust investment, some investors believe that certain AI stocks may hold greater promise for delivering higher returns in a shorter time frame.